Lisa Harding, MD

What Category Provider type are you? Psychiatry


What board certifications do you hold? ABPN
How many years have you been in ketamine practice? 2
What percentage of your work is clinical versus research? 90% clinical 10% research
Please describe any connections you have to major universities, research institutions and pharmaceutical companies, both financial and advisory/board? Clinical Instructor at Yale School of Medicine Department of Psychiatry. I am eligible to receive support from Yale to deliver mental health outreach projects in faith communities in CT.
What are your views regarding desirability and appropriateness of including and fostering the variety of practitioners who presently administer ketamine for mood disorders? I am one of the very few black Psychiatrists trained to deliver ketamine. To date, research shows how few minority patients are offered ketamine for mood disorders. Collaborating with colleagues across all spheres is critical to providing access to care, especially when it comes to marginalized populations.
What is your preferred route of administration of ketamine for mood disorders. What are your thoughts about the appropriateness or therapeutic value of other routes? In order of preference: 1. IV 2. Intranasal 3. IM

My approach to all therapies is centered on patient safety and sound scientific evidence.

How do you approach the problem of integrating the transient altered state we induce into the patient’s overall psychic economy? What is the practitioner’s responsibility in this regard? I do not see this as a problem but part of the therapeutic experience. My clinic is designed where the individual treatment rooms have ambient conditions for a mindful experience. I also have a Yoga room that once patients are clinically stable, they are invited to practice meditation in a private space.


My responsibility is true informed consent. Prior to treatment, everything is explained to the patient. While in treatment, the patient is monitored for clinical and psychological stability. We are close by to intervene pharmacologically if needed.

Please describe your present clinical practice. How will it look different in 5 years? I have an Interventional Psychiatric private practice. I specialize in treatment resistant depression and offer Spravato, ketamine and rTMS. In five years, I plan to open a partial day hospitalization program offering these services under one roof.
How do you envision ASKP3 growing over the next 4 years? I would like ASKP3 to continue having a strong voice in guiding the judicious administration of ketamine to our vulnerable patients. I would like us to have official representation within other societies (Anesthesia and Psychiatry) so that we are able to guide other specialties and influence national policy that govern the use of ketamine.